1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Kitazato Corporation

Kitazato Corporation

TTSE:368A
1,380.00
JPY
-27.00
(-1.92%)
52.56BMarket Cap
Oct 28Next Earn
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
233.7
252
257.55
273.69
- -
Basic EPS, GAAP
84.25
99.3
94.7
97.38
- -
Free Cash Flow per Basic Share
51.25
110.38
65.58
90.78
- -
Dividend per Share
30
50
40
41
- -
Book Value per Share
352.18
401.5
456.23
512.6
- -
Tangible Book Value per Share
350.05
399.55
454.7
511.43
- -
Basic Weighted Avg Shares
40
40
40
40
40
Sales/Revenue/Turnover
9,348
10,080
10,302
10,947
- -
Operating Margin (%)
54.87
58.66
56.13
53.52
- -
Depreciation Expense
162
177
175
190
- -
Net Income, GAAP
3,370
3,972
3,788
3,895
- -
Effective Tax Rate (%)
33.97
33.73
34
34.03
- -
Profit Margin (%)
36.05
39.4
36.77
35.58
- -
Working Capital
10,050
12,036
13,416
15,717
- -
LT Debt
- -
- -
- -
- -
- -
Total Equity
14,087
16,060
18,249
20,504
- -
Return on Invested Capital (%)
- -
24.3
20.95
19.03
- -
Return on Capital (%)
- -
26.36
22.09
20.11
- -
Return on Common Equity (%)
- -
26.35
22.08
20.1
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
59,200
52,560
53,000

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
14,957
17,147
- -
Cash, Cash Equivalents & STI
11,608
13,414
- -
Accounts Receivable, Net
1,102
1,561
- -
Inventories
2,026
1,999
- -
Total Current Liabilities
1,399
1,430
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
12.36%
Free Cash Flow
- -
- -
38.43%
Net Income, GAAP
- -
- -
2.82%
Sales/Revenue/Turnover
- -
- -
6.26%
Total Cash Common Dividend
- -
- -
2.5%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
10,302
2026
- -
- -
- -
- -
10,947
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
94.7
2026
- -
- -
- -
- -
97.38
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
40
2026
- -
- -
- -
- -
41
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Futoshi Inoue
Full Time Employees
83
Sector
Health technology
Industry
Pharmaceuticals: major
Address
100-10 Yanagishima Fuji SZ Japan 416-0932
IPO Date
Jun 25, 2025
Website
kitazato.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Kitazato Corporation researches, develops, manufactures, and markets medical devices, reagents, and related products for fertility treatment and assisted reproduction technologies. The company offers a comprehensive portfolio covering the entire IVF lifecycle, including oocyte retrieval needles; micro pipettes; embryo transfer (ET) and intrauterine insemination (IUI) catheters such as the RYDEN ET Catheter; culture media and oils like Hypure Oil Heavy; and the proprietary Cryotop Vitrification Method with associated kits including Ultra-Fast Vitri and Ultra-Fast Warming Kit. It supplies over 550 references to more than 3,000 clinics worldwide, with primary operations in Japan and global distribution across Asia, Europe, and other regions. Founded in 1998 and headquartered at 100-10 Yanagishima, Fuji, Shizuoka, Japan, the company, formerly known as Kitazato Biopharma Co., Ltd., listed on the Tokyo Stock Exchange Prime Market in June 2025 under ticker 368A.T following an initial public offering of approximately 14 million shares valued at up to JPY 21.6 billion. Recent developments include the launch of Ultra-Fast Vitrification Protocols and kits, expansion of IVF and andrology media ranges, and attainment of CE marking under EU Medical Device Regulation for the Ultra-Fast Warming Kit, alongside ongoing collaborations with leading clinics for product enhancements and best practice programs.